Literature DB >> 20625084

When does Parkinson disease start?

Rodolfo Savica1, Walter A Rocca, J Eric Ahlskog.   

Abstract

There is convincing evidence that the Parkinson disease neurodegenerative process begins many years before the onset of motor manifestations. Initial estimates based on nigral neuropathological findings or striatal dopamine imaging suggested a 5- to 6-year preclinical period. However, more recent evidence of Lewy body pathology in other neuronal populations preceding nigral involvement suggests that the preclinical phase may be much longer. Epidemiologic studies of nonmotor manifestations, such as constipation, anxiety disorders, rapid eye movement sleep behavior disorder (RBD), and anemia, suggest that the preclinical period extends at least 20 years before the motor manifestations. Olfactory impairment and depression may also precede the onset of motor manifestations; however, the lag time may be shorter. Recognition of a nonmotor preclinical phase spanning 20 or more years should guide the search for predictive biomarkers and the identification of risk or protective factors for Parkinson disease.

Entities:  

Mesh:

Year:  2010        PMID: 20625084     DOI: 10.1001/archneurol.2010.135

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  90 in total

1.  PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Authors:  Bin Zheng; Zhixiang Liao; Joseph J Locascio; Kristen A Lesniak; Sarah S Roderick; Marla L Watt; Aron C Eklund; Yanli Zhang-James; Peter D Kim; Michael A Hauser; Edna Grünblatt; Linda B Moran; Silvia A Mandel; Peter Riederer; Renee M Miller; Howard J Federoff; Ullrich Wüllner; Spyridon Papapetropoulos; Moussa B Youdim; Ippolita Cantuti-Castelvetri; Anne B Young; Jeffery M Vance; Richard L Davis; John C Hedreen; Charles H Adler; Thomas G Beach; Manuel B Graeber; Frank A Middleton; Jean-Christophe Rochet; Clemens R Scherzer
Journal:  Sci Transl Med       Date:  2010-10-06       Impact factor: 17.956

2.  Management of sexual dysfunction in Parkinson's disease.

Authors:  Gila Bronner; David B Vodušek
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

3.  The mesopontine rostromedial tegmental nucleus: an integrative modulator of the reward system.

Authors:  Heather N Lavezzi; Daniel S Zahm
Journal:  Basal Ganglia       Date:  2011-11

Review 4.  Cheaper, simpler, and better: tips for treating seniors with Parkinson disease.

Authors:  J Eric Ahlskog
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

5.  Pro-dromal sarcopenia.

Authors:  D L Waters
Journal:  J Nutr Health Aging       Date:  2011-12       Impact factor: 4.075

6.  Premotor Parkinson's disease: concepts and definitions.

Authors:  Andrew Siderowf; Anthony E Lang
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

7.  Motor map reliability and aging: a TMS/fMRI study.

Authors:  Keith M McGregor; Haley Carpenter; Erin Kleim; Atchar Sudhyadhom; Keith D White; Andrew J Butler; Jeffrey Kleim; Bruce Crosson
Journal:  Exp Brain Res       Date:  2012-03-31       Impact factor: 1.972

8.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

9.  Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection.

Authors:  Viviane Labrie; Patrik Brundin
Journal:  J Innate Immun       Date:  2017-09-02       Impact factor: 7.349

Review 10.  Amyotrophic lateral sclerosis--a model of corticofugal axonal spread.

Authors:  Heiko Braak; Johannes Brettschneider; Albert C Ludolph; Virginia M Lee; John Q Trojanowski; Kelly Del Tredici
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.